

Oral lyophilisate

CAUTIONARY AND ADVISORY LABELS 26

▶ **DDAVP Melt** (Ferring Pharmaceuticals Ltd)**Desmopressin (as Desmopressin acetate) 60 microgram** DDAVP Melt 60microgram oral lyophilisates sugar-free | 100 tablet [PoM] £50.53 DT = £50.53**Desmopressin (as Desmopressin acetate) 120 microgram** DDAVP Melt 120microgram oral lyophilisates sugar-free | 100 tablet [PoM] £101.07 DT = £101.07**Desmopressin (as Desmopressin acetate) 240 microgram** DDAVP Melt 240microgram oral lyophilisates sugar-free | 100 tablet [PoM] £202.14▶ **DesmoMelt** (Ferring Pharmaceuticals Ltd)**Desmopressin (as Desmopressin acetate)****120 microgram** DesmoMelt 120microgram oral lyophilisates sugar-free | 30 tablet [PoM] £30.34 DT = £30.34**Desmopressin (as Desmopressin acetate)****240 microgram** DesmoMelt 240microgram oral lyophilisates sugar-free | 30 tablet [PoM] £60.68 DT = £60.68▶ **Noqdirna** (Ferring Pharmaceuticals Ltd)**Desmopressin (as Desmopressin acetate) 25 microgram** Noqdirna 25microgram oral lyophilisates sugar-free | 30 tablet [PoM] £15.16 DT = £15.16**Desmopressin (as Desmopressin acetate)****50 microgram** Noqdirna 50microgram oral lyophilisates sugar-free | 30 tablet [PoM] £15.16 DT = £15.16**Nasal drops**▶ **DDAVP** (Ferring Pharmaceuticals Ltd)**Desmopressin acetate 100 microgram per 1 ml** DDAVP 100micrograms/ml intranasal solution | 2.5 ml [PoM] £9.72 DT = £9.72**Vasopressin**● **INDICATIONS AND DOSE****Pituitary diabetes insipidus**

▶ BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION

▶ Adult: 5–20 units every 4 hours

Initial control of oesophageal variceal bleeding

▶ BY INTRAVENOUS INFUSION

▶ Adult: 20 units, dose to be administered over 15 minutes

● **CONTRA-INDICATIONS** Chronic nephritis (until reasonable blood nitrogen concentrations attained) · vascular disease (especially disease of coronary arteries) unless extreme caution● **CAUTIONS** Asthma · avoid fluid overload · conditions which might be aggravated by water retention · epilepsy · heart failure · hypertension · migraine● **SIDE-EFFECTS** Abdominal pain · angina pectoris · bronchospasm · cardiac arrest · chest pain · diarrhoea · flatulence · fluid imbalance · gangrene · headache · hyperhidrosis · hypertension · musculoskeletal chest pain · nausea · pallor · peripheral ischaemia · tremor · urticaria · vertigo · vomiting● **PREGNANCY** Oxytocic effect in third trimester.● **BREAST FEEDING** Not known to be harmful.● **DIRECTIONS FOR ADMINISTRATION**▶ With intravenous use For *intravenous infusion* (argipressin), give intermittently in Glucose 5%; suggested concentration 20 units/100mL given over 15 minutes.● **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection**Solution for injection**▶ **Vasopressin (Non-proprietary)****Argipressin 20 unit per 1 ml** Argipressin 20units/1ml solution for injection ampoules | 10 ampoule [PoM] £754.86-£950.00 (Hospital only)**1.2 Syndrome of inappropriate antidiuretic hormone secretion****Other drugs used for Syndrome of inappropriate antidiuretic hormone secretion** Demeclocycline hydrochloride, p. 597**DIURETICS > SELECTIVE VASOPRESSIN V₂-RECEPTOR ANTAGONISTS****Tolvaptan**

14-May-2020

● **DRUG ACTION** Tolvaptan is a vasopressin V₂-receptor antagonist.● **INDICATIONS AND DOSE****JINARC[®]****Autosomal dominant polycystic kidney disease in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease (initiated by a specialist)**

▶ BY MOUTH

▶ Adult: Initially 60 mg daily in 2 divided doses for at least a week, 45 mg in the morning before breakfast, and then 15 mg taken 8 hours later; increased to 90 mg daily in 2 divided doses for at least a week, 60 mg in the morning before breakfast, and then 30 mg taken 8 hours later, then increased if tolerated to 120 mg daily in 2 divided doses, 90 mg in the morning before breakfast, and then 30 mg taken 8 hours later, dose titration should be performed cautiously; patients may down-titrate to lower doses based on tolerability

DOSE ADJUSTMENTS DUE TO INTERACTIONS▶ For *Jinarc[®]*, manufacturer advises reduce dose with concurrent use of potent CYP3A4 inhibitors—if daily dose 90 mg or 120 mg, reduce to 30 mg once daily (can be further reduced to 15 mg once daily if not tolerated); if daily dose 60 mg, reduce to 15 mg once daily. Manufacturer also advises reduce dose with concurrent use of moderate CYP3A4 inhibitors or ciprofloxacin—if daily dose 120 mg, reduce to 60 mg daily (45 mg in morning and 15 mg taken 8 hours later); if daily dose 90 mg, reduce to 45 mg daily (30 mg in morning and 15 mg taken 8 hours later); if daily dose 60 mg, reduce to 30 mg daily (15 mg in morning and 15 mg taken 8 hours later).**SAMSCA[®]****Hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (initiated in hospital or under specialist supervision)**

▶ BY MOUTH

▶ Adult: Initially 15 mg once daily, increased if necessary up to 60 mg once daily, a reduced starting dose of 7.5 mg once daily should be considered for patients at risk of overly rapid correction of serum-sodium concentration

● **CONTRA-INDICATIONS** Anuria · hypernatraemia · hypovolaemic hyponatraemia · impaired perception of thirst · volume depletion● **CAUTIONS****GENERAL CAUTIONS** Abnormal liver function tests and/or signs or symptoms of liver injury (do not initiate if the criteria for permanent discontinuation are met—consult product literature) · diabetes mellitus · patients at risk of